David Thomson MA MD FRCR
David Thomson qualified from Oxford University Medical School in 2004, achieving a First Class honours degree in Physiological Sciences (2001). As part of his postgraduate training he undertook a research Fellowship at the University of Manchester with attachment to the University of Pennsylvania, and was awarded a Doctor of Medicine (MD) research degree in 2015. He has an interest in medical education and completed a Postgraduate Certificate in Medical Education with Distinction (Edge Hill University, 2014). Dr Thomson was appointed Consultant Clinical Oncologist at The Christie (2015) and Honorary Senior Lecturer at The University of Manchester, specialising in the treatment of head and neck cancer. He is member of the National Cancer Research group for head and neck cancer, Principal Investigator for a number of portfolio studies, Deputy Chief Investigator for the NIMRAD trial (assessing the benefit of hypoxia modification using nimorazole with radiotherapy in those unsuitable for concurrent chemotherapy), Proton Beam Therapy National Panel Member and policy lead for Head and Neck Cancer and clinical lead for the implementation of electronic patient reported outcomes in head and neck cancer at The Christie. As the Clinical Director of the Greater Manchester Head and Neck Cancer Pathway Board, he is passionate about improving survival outcomes and long-term quality of life for patients treated for head and neck cancer.